BioCentury
ARTICLE | Clinical News

Mesoblast gains on Phase II spine fusion data

January 12, 2013 12:18 AM UTC

Mesoblast Ltd. (ASX:MSB; Pink:MBLTY) gained A$0.50 (10%) to A$5.74 on Friday after reporting data from an open-label, U.S. Phase II trial of the company's NeoFuse mesenchymal precursor cells (MPCs) to...